An update on the prevalence and characterization of H-PF4 antibodies in Asian-Indian patients

Seminars in Thrombosis and Hemostasis

Volumn 35, Issue 3, 2009, Pages 337-343

  Kannan, Meganathan ^c   Saxena, Renu ^a   Adiguzel, Cafer ^c   Fareed, Jawed ^a,b  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c NONE

Author keywords

Diagnosis; Heparin contaminant; Heparin PF4 antibody; Indian

Indexed keywords

FC RECEPTOR IIA; HEPARIN; HEPARIN PLATELET FACTOR 4 ANTIBODY; LOW MOLECULAR WEIGHT HEPARIN; ANTICOAGULANT AGENT; AUTOANTIBODY; THROMBOCYTE FACTOR 4;

ARTERY THROMBOSIS; CLINICAL FEATURE; DEEP VEIN THROMBOSIS; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETIC POLYMORPHISM; HEART INFARCTION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INDIAN; LABORATORY DIAGNOSIS; LUNG EMBOLISM; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; STROKE; THROMBOCYTE ACTIVATION; THROMBOCYTE POOR PLASMA; THROMBOCYTE RICH PLASMA; THROMBOCYTOPENIA; THROMBOSIS; BLOOD; IMMUNOASSAY; IMMUNOLOGY; INDIA;

ANTICOAGULANTS; AUTOANTIBODIES; HEPARIN; HUMANS; IMMUNOASSAY; INDIA; PLATELET ACTIVATION; PLATELET FACTOR 4; THROMBOCYTOPENIA;

EID: 67649220637     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0029-1222612     Document Type: Review

References (35)

1. Amiral J, Marfaing-Koka A, Poncz M, Meyer D. The biological basis of heparin-induced thrombocytopenia. Platelets 1998;9:77-91
2. Ahmad S, Untch B, Haas S, et al. Differential prevalence of anti-heparin-PF4 immunoglobulin subtypes in patients treated with clivarin and heparin: implications in the HIT pathogenesis. Mol Cell Biochem 2004;258:163-170 (Pubitemid 38268211)
3. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126(Suppl. 3):311S-337S
4. Fabris F, Ahmad S, Cella G, Jeske WP,Walenga JM, Fareed J. Pathophysiology of heparin-induced thrombocytopenia: clinical and diagnostic implications - a review. Arch Pathol Lab Med 2000;124:1657-1666 (Pubitemid 30846643)
5. Chong BH. Heparin-induced thrombocytopenia. J Thromb Haemost 2003;1:1471-1478
6. Castelli R, Cassinerio E, Cappellini MD, Porro F, Graziadei G, Fabris F. Heparin induced thrombocytopenia: pathogenetic, clinical, diagnostic and therapeutic aspects. Cardiovasc Hematol Disord Drug Targets 2007;7:153-162 (Pubitemid 47496572)
7. Brieger DB, Mak KH, Kottke-Marchant K. Heparin-induced thrombocytopenia. J Am Coll Cardiol 1998;31: 1449-1459
8. Fabris F, Ahmad S, Cella G, Jeske WP,Walenga JM, Fareed J. Pathophysiology of heparin-induced thrombocytopenia: clinical and diagnostic implications - a review. Arch Pathol Lab Med 1966;124:1657-1666
9. Brandt JT, Isenhart CE, Osborne JM, Ahmed A, Anderson CL. On the role of platelet Fc gamma RIIa phenotype in heparin-induced thrombocytopenia. Thromb Haemost 1995; 74:1564-1572 (Pubitemid 3014514)
10. Lehrnbecher TL, Foster CB, Zhu S, et al. Variant genotypes of FcgRIIA influence the development of Kaposi's sarcoma in HIV-infected men. Blood 2000;95:2386-2390 (Pubitemid 30167740)
11. Ohno H, Yokoi M. Intraoperative management for a patient with heparin-induced thrombocytopenia (HIT) undergoing off-pump coronary bypass surgery using argatroban, a direct thrombin inhibitor. Masui 2002;51:30-33 (Pubitemid 34131880)
12. Selleng K, Selleng S, Greinacher A. Heparin-induced thrombocytopenia in intensive care patients. Semin Thromb Hemost 2008;34:425-438
13. Prechel M, Walenga JM. The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update. Semin Thromb Hemost 2008;34:86-96 (Pubitemid 351640884)
14. Greinacher A, Kohlmann T, Strobel U, Sheppard JA, Warkentin TE. The temporal profile of the anti-PF4/heparin immune response. Blood 2008; December 23 (Epub ahead of print)
15. Krauel K, Fürll B, Warkentin TE, et al. Heparin-induced thrombocytopenia-therapeutic concentrations of danaparoid, unlike fondaparinux and direct thrombin inhibitors, inhibit formation of platelet factor 4-heparin complexes. J Thromb Haemost 2008;6:2160-2167
16. DiGiovanni CW. Current concepts review: heparin-induced thrombocytopenia. Foot Ankle Int 2008;29:1158-1167
17. Kannan M, Ahmad F, Ahmad S, Kale S, Fareed J, Saxena R. Heparin-PF4 antibodies in heparin induced thrombocytopenia: its relationship with FcgRIIa polymorphism. Am J Immunol. 2005;1:55-59
18. Hursting MJ, Verme-Gibboney CN. Risk factors for major bleeding in patients with heparin-induced thrombocytopenia treated with argatroban: a retrospective study. J Cardiovasc Pharmacol 2008;52:561-566
19. Kawano H, Toyoda K, Miyata S, et al. Heparin-induced thrombocytopenia: a serious complication of heparin therapy for acute stroke. Cerebrovasc Dis 2008;26:641-649
20. Jiji RS, Michaels AD. Heparin-induced thrombocytopenia (HIT) causing pulmonary emboli during coronary intervention. Catheter Cardiovasc Interv 2008;72:819-822
21. Kannan M, Ahmad S, Ahmad F, et al. Functional characterization of antibodies against heparin-PF4 complex in heparin-induced thrombocytopenia patients in Asian-Indians: relevance to inflammatory markers. Blood Coagul Fibrinolysis 2005;16:487-490 (Pubitemid 41794942)
22. Walenga JM, Jeske WP, Wood JJ, Ahmad S, Lewis BE, Bakhos M. Laboratory tests for heparin-induced thrombocytopenia: a multicenter study. Semin Hematol 1999;36(Suppl 1): 22-28 (Pubitemid 29045507)
23. Lee DH, Warkentin TE, Denomme GA, Hayward CP, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia: detection of platelet microparticles using flow cytometry. Br J Haematol 1996;95:724-731
24. Kannan M, Ahmed R, Kale S, Ahmad S, Fareed J, Saxena R. Laboratory diagnosis of heparin-induced thrombocytopenia in Asian Indians as investigated with functional and immunologic methods. Clin Appl Thromb Hemost 2004; 10:51-54 (Pubitemid 38543717)
25. Barginear MF, Donahue L, Allen SL, et al. Heparin-induced thrombocytopenia complicating hemodialysis. Clin Appl Thromb Hemost 2008;14:105-107
26. Bansal V, Cunanan J, Adiguzel C, Litinas E, Nelson K, Fareed J. A higher prevalence of HIT antibodies in patients may be due to contaminated heparin. Blood 2008;112: 3022
27. Zhang Z, Weïwer M, Li B, Kemp MM, Daman TH, Linhardt RJ. Oversulfated chondroitin sulfate: impact of a heparin impurity, associated with adverse clinical events, on low-molecular-weight heparin preparation. J Med Chem 2008; 51:5498-5501
28. Kishimoto TK, Viswanathan K, Ganguly T, et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008;358: 2457-2467 (Pubitemid 351793019)
29. BellWR, Royall RM. Heparin-associated thrombocytopenia: a comparison of three heparin preparations. N Engl J Med 1980;303:902-907
30. Harenberg J, Wehling M. Current and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa. Semin Thromb Hemost 2008;34:39-57 (Pubitemid 351640881)
31. Fareed J, Hoppensteadt DA, Fareed D, et al. Survival of heparins, oral anticoagulants, and aspirin after the year 2010. Semin Thromb Hemost 2008;34:58-73 (Pubitemid 351640882)
32. Warkentin TE, Greinacher A, Koster A, Lincoff A; Mon behalf of the American College of Chest Physicians. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(6, Suppl):340S-380S
33. Fareed J, Walenga J, Messmore H, Baker W, Bick M. In memoriam: Rodger L. Bick, MD, PhD, FACP-a wonderful friend, great clinician, and brilliant educator. Clin Appl Thromb Hemost 2009;15:5-7
34. Nand S, Wong W, Yuen B, Yetter A, Schmulbach E, Gross Fisher S. Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution. Am J Hematol 1997;56:12-16 (Pubitemid 27398052)
35. Warkentin TE. Heparin-induced thrombocytopenia: a tenyear retrospective. Annu Rev Med 1999;50:129-147